BASi Appoints Chief Operating Officer
Bioanalytical Systems, Inc announced today that Anthony S. Chilton, Ph.D. is joining the Company as Chief Operating Officer, Scientific Services, effective December 1, 2008.
Anthony S. Chilton to Join BASi as Chief Operating Officer, Scientific Services
WEST LAFAYETTE, IN, November 14, 2008 – Bioanalytical Systems, Inc (Nasdaq: BASI) (“the Company”) announced today that Anthony S. Chilton, Ph.D. is joining the Company as Chief Operating Officer, Scientific Services, effective December 1, 2008. Dr. Chilton will have responsibility for the scientific services provided to the Company’s customers from three locations in the U.S. and one in the U.K.
Dr. Chilton has over 30 years of experience as a scientist and executive in leading life sciences companies in England, Canada and the United States. For the past two years, Dr. Chilton was in charge of early development programs at Atherogenics, Inc. of Alpharetta, Ga. For the two years prior to that, Dr. Chilton provided consulting and advisory services to various pharmaceutical companies. Earlier, he was Vice President of the Biopharmaceutical Development Division of Cardinal Health Inc., which he joined through a predecessor company in 1998 that was acquired by Cardinal in 2002. Previously, Dr. Chilton spent three years with life sciences companies in Canada, prior to which he held positions in his native United Kingdom. Dr. Chilton received his bachelor’s degree in Chemistry from the University of East Anglia in 1981, and his Ph.D. in Analytical Chemistry from the University of Hertfordshire in 1993.
As part of his compensation package, the Company has agreed to grant Dr. Chilton incentive options to purchase 30,000 common shares under its 2008 Employee Incentive Stock Option Plan at the per-share market price at the close of business on the last trading day prior to the date Dr. Chilton commences employment with the Company. The option grants are contingent upon Dr. Chilton commencing employment with the Company.
BASi provides contract research services and unique analytical instruments to the world’s leading drug development companies. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new drugs to market. Visit www.BASInc.com for more information about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, the retention of key Company personnel, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the Company’s filings with the Securities and Exchange Commission.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
